76 articles - From Friday Jul 03 2026 to Friday Jul 10 2026
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Am J Gastroenterol |
|---|
| ACG Clinical Guideline: Colonic Diverticulitis.
Antibiotic use is appropriate for patients with high-risk features, immunocompromise, frailty, or inability to ensure safe outpatient management. Patients with recurrent, uncomplicated diverticulitis that significantly affects quality of life should be referred for surgical consultation to discuss the risks and benefits of elective colon resection. |
| Dietary Guidelines 2025-2030 For Americans Are Concerning For Liver Health.
HEI-2020 and z-score models identify multiple protective and adverse dietary components associated with SLD and fibrosis. The findings underscore the importance of component-level nuance-particularly regarding protein sources and alcohol intake-when formulating dietary guidance for liver health. |
meta-analyses and systematic reviews
| Gastroenterology |
|---|
| Acupuncture versus sham non-acupoint acupuncture for irritable bowel syndrome: a systematic review and meta-analysis.
We discovered acupuncture significantly improved IBS patients' response rate and overall symptom at the end of treatment, as compared to sham non-acupoint acupuncture. Due to the significant heterogeneity and low certainty of evidence, our work merits more confirmation by large-scale and high-quality trials. |
| Gut |
| Outcome scoring systems for locoregional therapy in hepatocellular carcinoma: a systematic review.
Several outcome scoring systems are promising for specific LRTs and populations. However, most models have high risk of bias, underscoring the need for further development and validation. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
| Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis-Randomized, Double-Blind, Crossover Clinical Trial.
Our study supported the efficacy and safety of Lemborexant, particularly at 5 mg, against sleep problems in cirrhosis. Larger studies with longer follow-up are warranted to strengthen evidence. NCT07480096. |
| Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group.
QoL, and not only disease activity as assessed using a conventional disease activity score, may play a significant role in the decision to initiate ustekinumab. Systematic integration of QoL measures into routine care may improve patient care and treatment outcomes. |
| Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi-Centre Matched Analysis.
IBD is associated with increased MPN risk, and IBD-MPNs coexistence is associated with worse IBD-related complications and malignancy risk. |
| Clin Gastroenterol Hepatol |
| Association of metabolic dysfunction-associated steatotic liver disease onset age with risk of incident type 2 diabetes.
MASLD onset at any age is associated with increased risk of T2D, with earlier onset conferring progressively greater risk. This highlights the importance of preventing, or at least delaying MASLD onset, particularly in young adults. |
| Randomized trial comparing 5-year follow-up of first-line infliximab to conventional therapy in paediatric Crohn's disease.
After 5-years follow-up in the TISKids trial, we found that almost al patients required additional CD-related treatment, irrespective of induction therapy with five infusion of FL-IFX or conventional treatment. FL-IFX delayed the need for additional biological treatment, indicating its potential as preferred treatment option for patients with moderate-to-severe CD at diagnosis. These findings underscore that patients with moderate-to-severe CD require early and maintained treatment with infliximab. |
| Endoscopy |
| Evaluating human-AI interaction in optical diagnosis of early colorectal carcinoma through endoscopist responses to simulated artificial intelligence: a multinational online study.
Inappropriate AI response is an issue in human-AI interaction for the optical diagnosis of CRCs. Before using AI, endoscopists could inform themselves on their own and AI's optical diagnostic performance to possibly improve interaction. |
| Technical and Clinical Success of Endoscopic Hand-Suturing: A European Multicenter Study.
EHS demonstrated high technical and in-hospital clinical success with a low observed short-term adverse event rate. Further studies are needed to assess the performance for complex defects. |
| Gastrointest Endosc |
| Comparison of left lateral and supine positioning for EUS-guided portal pressure gradient measurements.
PPG measurements were consistent between left lateral and supine positions. Under moderate sedation, the left lateral position was associated with fewer coughing events and may improve procedural safety and convenience. |
| EUS Versus Transjugular Approaches for Portal Pressure Measurement and Liver Biopsy: A Cost-Effectiveness Analysis.
In patients requiring PPG and LB, EUS demonstrated reduced costs and higher effectiveness compared to TJ. Improved cost-effectiveness was driven by EUS' higher clinical success rates and cost-savings due to its one-stop shop approach. With evidence now demonstrating EUS' superior clinical and economic value, these findings support wider clinical adoption. |
| LOCAL RECURRENCE AFTER COLORECTAL ENDOSCOPIC SUBMUCOSAL DISSECTION: A LARGE INTERNATIONAL WESTERN MULTICENTER STUDY.
In this multicenter non-Asian study, local recurrence after colorectal ESD was 1.5% and 0.8% for very low-risk lesions. Severe submucosal fibrosis and R1/Rx resection were independently associated with local recurrence. Our data support current recommendations for SC at 12 months after ESD and raises the possibility of a longer interval for very low-risk lesions. |
| SINGLE-BLINDED RANDOMIZED CONTROLLED TRIAL COMPARING THE EFFECT OF UNDERWATER VERSUS CARBON DIOXIDE INSUFFLATION DURING PERORAL ENDOSCOPIC MYOTOMY ON POST-PROCEDURAL PAIN (U-POEM TRIAL).
U-POEM was safe, effective, and associated with lower post-procedure pain scores when compared to CO2-POEM (U-POEM trial NCT06918730). |
| The Impact of Confocal Endomicroscopy Combined with Standard Diagnostics in Evaluating Large Pancreatic Cystic Lesions: An International Interobserver Study.
When combined with standard diagnostic evaluation, including cyst fluid glucose analysis, EUS-nCLE significantly enhances accuracy for classifying and identifying pancreatic cystic lesion subtypes. These results support incorporating nCLE into diagnostic algorithms, particularly for larger cysts where precise management decisions are crucial. |
| Venous Thromboembolism Following Endoscopic Sleeve Gastroplasty.
The incidence of VTE following ESG is extremely low in this large prospective multicenter database. Although events occurred in fewer than 0.5% of cases, a majority of patients who developed DVT or PE after ESG did not receive pharmacologic or mechanical prophylaxis. Decisions surrounding the selection of VTE prophylaxis should be made based on a patient's co-morbidities, with consideration for low-risk interventions like mechanical prophylaxis in al patients undergoing ESG. |
| Gut |
| Cross-definition GWAS of IBS in 2.8 million individuals reveals cardiometabolic and triglyceride-linked mechanisms.
This study provides the most comprehensive assessment of IBS genetics to date, demonstrating reproducible polygenic inheritance. We link IBS risk to convergent neurogastrointestinal and novel cardiometabolic mechanisms, highlight specific biological pathways and actionable mechanisms and outline translational opportunities emerging from integrated computational analyses. |
| Dysregulated sphingolipid metabolismdrives pancreatic carcinogenesis through plasma membrane Kras enrichment.
In summary, SMPD1 regulated plasma membrane sequestration of Kras G12D represents a potential therapeutic target within the Kras signalling pathway for intractable PDAC. |
| Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study.
Postoperative GLP-1RA initiation, compared with DPP-4i initiation, was associated with delayed recurrence and longer OS; prospective confirmation is warranted. |
| IL-10-neutralising autoantibodies in paediatric-onset inflammatory bowel disease.
In paediatric autoimmune and inflammatory gut diseases, IL-10 neutralising autoantibodies were detected only among patients with IBD without known genetic aetiology. Patients had heterogeneous clinical characteristics and IL-10 autoantibodies persisted under standard immunosuppressive treatment but disappeared following HSCT and may have declined with colectomy or ileostomy. Screening for IL-10 autoantibodies via functional assays may identify a subgroup of patients with distinct aetiology and therapeutic needs. |
| SMOC2 mediates GLI1+ mesenchymal cell-driven fibrostenosis and predicts postoperative recurrence in Crohn's disease.
GLI1+ mesenchymal cells drive intestinal fibrostenosis through SMOC2-mediated niche formation. SMOC2 may serve as a predictive biomarker for postoperative recurrence and a potential therapeutic target for CD. |
| USP20 promotes CD8<sup>+</sup> T cell exhaustion and impairs KRAS<sup>G12D</sup> inhibitor efficacy by orchestrating cholesterol metabolism and autophagy in pancreatic cancer.
USP20 acts as a critical metabolic checkpoint that orchestrates CD8 + T cell exhaustion and therapeutic response. Targeting the USP20-cholesterol-autophagy axis represents a promising strategy to reverse immune suppression and unlock the full potential of KRAS G12D inhibitors in PDAC. |
| J Hepatol |
| Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort.
HCC remains the main determinant of mortality. HBsAg loss rate increases after year-10, but it remains low being higher in older, initially HBeAg-positive patients. |
| Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.
Safety profiles of durvalumab plus seven gemcitabine-based chemotherapy regimens were manageable, and shorter durvalumab infusion duration (30 minutes vs 60 minutes) did not increase infusion-related reactions. Efficacy data are indicative of potential clinical activity across treatment arms. These findings demonstrate the feasibility of combining durvalumab with alternative gemcitabine-based regimens in a broad aBTC population. Impact and implications The choice of gemcitabine-based chemotherapy backbones for the treatment of advanced biliary tract cancer (aBTC) varies globally and their use in conjunction with immunotherapy has not been fully investigated. The TOURMALINE phase IIIb study demonstrated manageable safety and efficacy data showed potential clinical activity in a close-to-real-world population of participants with aBTC receiving durvalumab plus one of seven gemcitabine-based chemotherapy regimens. These findings point towards the feasibility of combining durvalumab with different gemcitabine-based chemotherapy regimens, even in participants with less favourable disease characteristics. Clinical trial number NCT05771480 TRIAL REGISTRATION ClinicalTrials.gov NCT05771480; |
| Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trial.
Ivonescimab plus chemotherapy showed potential anti-tumor activity and tolerable safety as first-line treatment of aBTC patients. Exploratory analyses suggest that MAP2K7 may serve as a candidate biomarker of resistance and a potential therapeutic target for optimizing ivonescimab-based therapy of aBTC patients. Impact and implications Currently, the standard of care for first-line therapy in patients with aBTC is the addition of immune checkpoint inhibitors to chemotherapy based on the TOPAZ-1 and KEYNOTE-966 trials. However, this new regimen only improved OS by less than 2 months. The ORR of 66.7%, DCR of 100% and the median overall survival of 16.8 months were observed with ivonescimab plus chemotherapy. This study provides evidence supporting the potential role of ivonescimab plus chemotherapy as a first-line therapy for patients with treatment-naive unresectable locally advanced or metastatic BTC. |
| Validation of a pan-ELastography Machine-learning (ELM) score to predict clinically significant portal hypertension in compensated advanced chronic liver disease.
The ELM Score outperformed current Baveno criteria and markedly reduced gray zones across elastography modalities, supporting broader, safer, and non-invasive identification of ACLD patients with HVPG-defined CSPH who may be candidates for NSBB therapy. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
| Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine.
Biomarkers are the core tools for precision medicine in liver transplantation for HCC. Despite challenges in standardization and clinical application, combining traditional biomarkers with multi-omics and liquid biopsy technologies holds promise for further improving patient prognosis. |
| Editorial: Dissecting the Natural History of Recurrent Pancreatitis. |
| Editorial: Fatigue in Disorders of Gut-Brain Interaction-An Important Symptom to Recognise. |
| Editorial: Mind the Gap-Peripheral Immune Signatures of HBV Cirrhosis in an Underserved Population. |
| Editorial: Non-Selective Beta-Blockers in Decompensated Cirrhosis-More Friends Than Foes. |
| J Hepatol |
| Unveiling the Biology of Liver Fibrosis: A Miniseries on the Mechanisms, Diagnostics, and Reversibility of Liver Fibrosis. |
| When Biology Pushes Back: Lessons From HBsAg-Targeting Therapies in Hepatitis Delta. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Calendar of Courses, Symposiums and Conferences. |
| Designing and Interpreting Large Database Studies in GI and Hepatology. |
| Molecular Nonendoscopic Tests for the Early Detection of Esophageal Squamous Carcinoma and High-Grade Dysplasia: Promising Progress. |
| Clin Gastroenterol Hepatol |
| ELEVATED CARBOHYDRATE ANTIGEN 19-9 IN PATIENTS WITH INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS AND CANCER RISK. |
| Educating the Artificial Intelligence-Augmented Clinician: Theories and Frameworks for Artificial Intelligence-Enhanced Education in Gastroenterology. |
| Endoscopy |
| A forward-viewing endoscope and a rotatable sphincterotome successfully enabled biliary intervention with esophageal stenosis. |
| A novel cold-cutting direct-deployment stent for endoscopic ultrasound-guided biliary drainage: a porcine feasibility study. |
| An unusual case of a hypervascular solid pancreatic lesion: all that glitters is not gold. |
| Endoscopic removal of a nasogastric tube inadvertently stapled to the gastric stump. |
| Endoscopic ultrasound guided bypass of malignant afferent limb obstruction with an electrocautery-enhanced lumen‑apposing metal stent. |
| Holmium:yttrium-aluminum-garnet laser-assisted retrieval of an embedded fully covered self-expandable metallic stent for benign biliary strictures. |
| Novel anchor ring-shaped thread countertraction for colorectal endoscopic submucosal dissection beyond the hepatic flexure. |
| Rescue endoscopic vacuum therapy after failed surgical repair of a perforated gastric ulcer. |
| Retrieval of a migrated lumen-apposing metal stent from a pancreatic fluid collection using a balloon enteroscopy overtube. |
| Reverse-view dual-traction endoscopic submucosal enucleation of a large gastric cardia gastrointestinal stromal tumor. |
| Robotic traction-assisted en bloc endoscopic resection of a large laterally spreading tumor in the descending duodenum. |
| Gastroenterology |
| A Kidney Transplant Recipient with Severe Chronic Diarrhea and Villous Atrophy. |
| An Unusual Cause of Chronic Hematochezia. |
| The Management of Fulminant C. difficile Infection in an Immunocompromised Patient: Balancing Risk and Necessity. |
| Gut |
| Safety and efficacy of extended surveillance intervals following colorectal endoscopic submucosal dissection: an international multicentre study. |
| Simple and dynamic endoscope tip traction to facilitate gastric ESD in difficult locations. |
| J Hepatol |
| Exercise-induced liver-to-brain communication in aging and Alzheimer's disease. |
| Optimising the screening strategy for early-stage hepatocellular carcinoma. |
| Retraction notice to "Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population" [J Hepatol 58 (2013) 271-277]. |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Letter on 'Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated MASH Cirrhosis for Fibrosis Regression and MASH Resolution'. Authors' Reply. |
| Letter on: Pre-Emptive Initiation of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema Improves Outcomes: A Randomized Controlled Trial. |
| Letter: HBsAg Loss After COVID-19 Vaccination: Implications for HBV Screening, Immunity Monitoring, and Health Worker Protection in LMICs. Authors' Reply. |
| Letter: Interpretation of Cognitive and Clinical Outcomes in the Randomised Trial of Rifaximin for Covert Hepatic Encephalopathy. |
| Letter: Non-Invasive Tests After Semaglutide in MASH as Disease-Activity Readouts Rather Than Response Biomarkers. |
| Letter: Nuanced Interpretation of Faecal Calprotectin During Maintenance of Ulcerative Colitis Treatment: Sweet Spots and Pitfalls. |
| Letter: Reconciling Histological Fibrosis Improvement With Magnetic Resonance Elastography After Sleeve Gastrectomy. |
| Letter: Severity-Informed Enrichment for Recurrent Acute Pancreatitis Trials. |
| Letter: Severity-Informed Enrichment for Recurrent Acute Pancreatitis Trials. Authors' Reply. |
| Clin Gastroenterol Hepatol |
| What Does "Non-Intensive Surveillance" Mean After Curative ESD for Low-Risk T1 Colorectal Cancer? |
| Gastroenterology |
| A Clinical Perspective on Comparative Models of Pancreatic Cyst Surveillance. |
| Anorectal Disorders: Do not throw the baby out with the dirty water. |
| Rome V Criteria for Anorectal Disorders: The Good and the Useful. |
| Two trials with two different answers: potential for Bayesian re-analysis in a Crohn's disease clinical trial. |
| When one trial is not enough: Lessons from darvadstrocel approval and withdrawal. |
| Gut |
| Missing barrier in coeliac disease: why the gut vascular barrier matters. |
| Serum creatinine as both yardstick and predictor: reading chronic kidney disease in the global CLEARED cohort. |
| J Hepatol |
| Moving Too Fast? A Meta-Analysis Calls for Caution on TNF Inhibitors as First-Line Therapy for Autoimmune Hepatitis. |